JP7249331B2 - 器官の生存率を改善する方法 - Google Patents
器官の生存率を改善する方法 Download PDFInfo
- Publication number
- JP7249331B2 JP7249331B2 JP2020511359A JP2020511359A JP7249331B2 JP 7249331 B2 JP7249331 B2 JP 7249331B2 JP 2020511359 A JP2020511359 A JP 2020511359A JP 2020511359 A JP2020511359 A JP 2020511359A JP 7249331 B2 JP7249331 B2 JP 7249331B2
- Authority
- JP
- Japan
- Prior art keywords
- organ
- ppm
- perfusion system
- composition
- organ perfusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000056 organ Anatomy 0.000 title claims description 405
- 230000004083 survival effect Effects 0.000 title claims description 25
- 239000000203 mixture Substances 0.000 claims description 208
- 239000007789 gas Substances 0.000 claims description 184
- 230000010412 perfusion Effects 0.000 claims description 95
- 210000004072 lung Anatomy 0.000 claims description 81
- 238000002054 transplantation Methods 0.000 claims description 66
- 230000002438 mitochondrial effect Effects 0.000 claims description 39
- 210000002216 heart Anatomy 0.000 claims description 35
- 208000028867 ischemia Diseases 0.000 claims description 32
- 210000003734 kidney Anatomy 0.000 claims description 31
- 230000004898 mitochondrial function Effects 0.000 claims description 31
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 29
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 29
- DZTHIGRZJZPRDV-UHFFFAOYSA-N N-acetyltryptophan Chemical compound C1=CC=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-UHFFFAOYSA-N 0.000 claims description 29
- 229960005480 sodium caprylate Drugs 0.000 claims description 29
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 claims description 29
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 14
- 208000007204 Brain death Diseases 0.000 claims description 12
- 210000004087 cornea Anatomy 0.000 claims description 7
- 210000000936 intestine Anatomy 0.000 claims description 7
- 210000004185 liver Anatomy 0.000 claims description 7
- 210000000496 pancreas Anatomy 0.000 claims description 7
- 210000001541 thymus gland Anatomy 0.000 claims description 7
- 238000002513 implantation Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 213
- 238000000034 method Methods 0.000 description 143
- 230000000694 effects Effects 0.000 description 62
- 206010063837 Reperfusion injury Diseases 0.000 description 29
- 230000001965 increasing effect Effects 0.000 description 27
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 26
- 239000000243 solution Substances 0.000 description 23
- 108010061951 Methemoglobin Proteins 0.000 description 22
- 208000010496 Heart Arrest Diseases 0.000 description 17
- 230000002779 inactivation Effects 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- 208000014674 injury Diseases 0.000 description 15
- 230000004792 oxidative damage Effects 0.000 description 15
- 238000009423 ventilation Methods 0.000 description 15
- 230000006378 damage Effects 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 230000007423 decrease Effects 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 12
- 230000010410 reperfusion Effects 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- 230000035899 viability Effects 0.000 description 11
- 101000708493 Alternaria alternata Superoxide dismutase [Mn], mitochondrial Proteins 0.000 description 10
- 102000015782 Electron Transport Complex III Human genes 0.000 description 10
- 108010024882 Electron Transport Complex III Proteins 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 8
- 230000002685 pulmonary effect Effects 0.000 description 8
- 230000008733 trauma Effects 0.000 description 7
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 6
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 6
- 206010038669 Respiratory arrest Diseases 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 210000001147 pulmonary artery Anatomy 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036593 pulmonary vascular resistance Effects 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 210000003437 trachea Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 4
- 230000005779 cell damage Effects 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 208000037887 cell injury Diseases 0.000 description 4
- 230000003727 cerebral blood flow Effects 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000004660 morphological change Effects 0.000 description 4
- 210000003516 pericardium Anatomy 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 4
- 108010052500 Calgranulin A Proteins 0.000 description 3
- 108010052495 Calgranulin B Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100032442 Protein S100-A8 Human genes 0.000 description 3
- 102100032420 Protein S100-A9 Human genes 0.000 description 3
- 210000002376 aorta thoracic Anatomy 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000001746 atrial effect Effects 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- -1 etc. Chemical compound 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 210000003492 pulmonary vein Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 206010003497 Asphyxia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108700027941 Celsior Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 102100037907 High mobility group protein B1 Human genes 0.000 description 2
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 102000054727 Serum Amyloid A Human genes 0.000 description 2
- 108700028909 Serum Amyloid A Proteins 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000006931 brain damage Effects 0.000 description 2
- 231100000874 brain damage Toxicity 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 238000007675 cardiac surgery Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 210000002837 heart atrium Anatomy 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- 229910052754 neon Inorganic materials 0.000 description 2
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000002620 vena cava superior Anatomy 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- ORFOPKXBNMVMKC-DWVKKRMSSA-O (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-O 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000023329 Gun shot wound Diseases 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 description 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001601 blood-air barrier Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000003685 cricoid cartilage Anatomy 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000029036 donor selection Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 230000002806 hypometabolic effect Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 210000001370 mediastinum Anatomy 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 208000005135 methemoglobinemia Diseases 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000000082 organ preservation Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 210000003102 pulmonary valve Anatomy 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910001868 water Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/14—Mechanical aspects of preservation; Apparatus or containers therefor
- A01N1/142—Apparatus
- A01N1/143—Apparatus for organ perfusion
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B2017/00969—Surgical instruments, devices or methods used for transplantation
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022123251A JP2022140622A (ja) | 2017-08-25 | 2022-08-02 | 器官の生存率を改善する方法 |
| JP2024137625A JP2024159817A (ja) | 2017-08-25 | 2024-08-19 | 器官の生存率を改善する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762550463P | 2017-08-25 | 2017-08-25 | |
| US62/550,463 | 2017-08-25 | ||
| PCT/US2018/048028 WO2019040921A1 (en) | 2017-08-25 | 2018-08-24 | METHODS OF ENHANCING VIABILITY OF AN ORGAN |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022123251A Division JP2022140622A (ja) | 2017-08-25 | 2022-08-02 | 器官の生存率を改善する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531529A JP2020531529A (ja) | 2020-11-05 |
| JP2020531529A5 JP2020531529A5 (enExample) | 2021-08-05 |
| JP7249331B2 true JP7249331B2 (ja) | 2023-03-30 |
Family
ID=65434015
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511359A Active JP7249331B2 (ja) | 2017-08-25 | 2018-08-24 | 器官の生存率を改善する方法 |
| JP2022123251A Pending JP2022140622A (ja) | 2017-08-25 | 2022-08-02 | 器官の生存率を改善する方法 |
| JP2024137625A Pending JP2024159817A (ja) | 2017-08-25 | 2024-08-19 | 器官の生存率を改善する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022123251A Pending JP2022140622A (ja) | 2017-08-25 | 2022-08-02 | 器官の生存率を改善する方法 |
| JP2024137625A Pending JP2024159817A (ja) | 2017-08-25 | 2024-08-19 | 器官の生存率を改善する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US11044904B2 (enExample) |
| EP (1) | EP3672403A4 (enExample) |
| JP (3) | JP7249331B2 (enExample) |
| KR (2) | KR102708577B1 (enExample) |
| CN (1) | CN111107742A (enExample) |
| AU (2) | AU2018322317B2 (enExample) |
| CA (1) | CA3073399A1 (enExample) |
| MX (1) | MX2020001853A (enExample) |
| WO (1) | WO2019040921A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3030789A1 (en) | 2016-07-13 | 2018-01-18 | The Trustees Of Columbia University In The City Of New York | Cross-circulation platform for recovery, regeneration, and maintenance of extracorporeal organs |
| AU2018322317B2 (en) * | 2017-08-25 | 2023-11-23 | Mallinckrodt Pharmaceuticals Ireland Limited | Methods to improve organ viability |
| CN110583620A (zh) * | 2019-08-26 | 2019-12-20 | 广东顺德工业设计研究院(广东顺德创新设计研究院) | 离体肺脏机械灌注的调温设备及方法、装置 |
| CN112106766B (zh) * | 2020-11-18 | 2021-03-12 | 中山大学附属第一医院 | 一种离体心肺联合灌注系统及灌注方法 |
| CN118142012B (zh) * | 2024-03-20 | 2025-05-13 | 中国人民解放军总医院第四医学中心 | 离断肢体血液交叉循环系统 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005500875A (ja) | 2001-06-21 | 2005-01-13 | ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド | 組織および臓器移植の転帰を改善しかつアポトーシスを抑制する一酸化炭素 |
| WO2008157393A1 (en) | 2007-06-15 | 2008-12-24 | Ikaria, Inc. | Compositions comprising sulfide alone or in combination with nitric oxide and their use to |
| JP2017503762A (ja) | 2013-03-15 | 2017-02-02 | マリンクロット ホスピタル プロダクツ アイピー リミテッド | ｅｘ ｖｉｖｏ液状物中への一酸化窒素の投与及びモニタリング |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5338662A (en) * | 1992-09-21 | 1994-08-16 | Bio-Preserve Medical Corporation | Organ perfusion device |
| GB9908335D0 (en) * | 1999-04-12 | 1999-06-09 | Univ Cambridge Tech | Methods and means for extracorporeal organ perfusion |
| AU2001241908A1 (en) * | 2000-03-08 | 2001-09-17 | Frederick A. Gage | Kidney perfusion solution containing nitric oxide donor |
| US7504201B2 (en) * | 2004-04-05 | 2009-03-17 | Organ Recovery Systems | Method for perfusing an organ and for isolating cells from the organ |
| US20060160062A1 (en) * | 2005-01-14 | 2006-07-20 | Young Lindon H | Perfusion and/or preservation solution for organs |
| JP4935242B2 (ja) * | 2006-08-24 | 2012-05-23 | ニプロ株式会社 | 脂肪酸を含有するｓ−ニトロソタンパク質とその製法 |
| WO2008063868A2 (en) | 2006-11-07 | 2008-05-29 | The General Hospital Corporation | Attenuation of vasoactive oxygen carrier-induced vasoconstriction |
| AU2011336358B2 (en) | 2010-12-03 | 2016-09-29 | VERO Biotech LLC. | Nitric oxide treatments |
| JP2019505569A (ja) | 2015-12-10 | 2019-02-28 | ベロ バイオテック エルエルシー | 血漿遊離ヘモグロビンを除去するための方法及び装置 |
| DE102017204681A1 (de) | 2017-03-21 | 2018-09-27 | Robert Bosch Gmbh | Vorrichtung zum Auslösen einer externen Schutzfunktion |
| AU2018322317B2 (en) * | 2017-08-25 | 2023-11-23 | Mallinckrodt Pharmaceuticals Ireland Limited | Methods to improve organ viability |
-
2018
- 2018-08-24 AU AU2018322317A patent/AU2018322317B2/en active Active
- 2018-08-24 WO PCT/US2018/048028 patent/WO2019040921A1/en not_active Ceased
- 2018-08-24 EP EP18848433.1A patent/EP3672403A4/en active Pending
- 2018-08-24 CA CA3073399A patent/CA3073399A1/en active Pending
- 2018-08-24 KR KR1020207007478A patent/KR102708577B1/ko active Active
- 2018-08-24 US US16/112,297 patent/US11044904B2/en active Active
- 2018-08-24 CN CN201880059363.9A patent/CN111107742A/zh active Pending
- 2018-08-24 JP JP2020511359A patent/JP7249331B2/ja active Active
- 2018-08-24 MX MX2020001853A patent/MX2020001853A/es unknown
- 2018-08-24 KR KR1020247031003A patent/KR20240142604A/ko active Pending
-
2021
- 2021-06-28 US US17/360,916 patent/US11950590B2/en active Active
-
2022
- 2022-08-02 JP JP2022123251A patent/JP2022140622A/ja active Pending
-
2024
- 2024-01-10 US US18/409,181 patent/US12285008B2/en active Active
- 2024-01-25 AU AU2024200468A patent/AU2024200468A1/en active Pending
- 2024-08-19 JP JP2024137625A patent/JP2024159817A/ja active Pending
-
2025
- 2025-04-02 US US19/098,522 patent/US20250228235A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005500875A (ja) | 2001-06-21 | 2005-01-13 | ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド | 組織および臓器移植の転帰を改善しかつアポトーシスを抑制する一酸化炭素 |
| WO2008157393A1 (en) | 2007-06-15 | 2008-12-24 | Ikaria, Inc. | Compositions comprising sulfide alone or in combination with nitric oxide and their use to |
| JP2010530001A (ja) | 2007-06-15 | 2010-09-02 | イカリア， インコーポレイテッド | 硫化物単独または一酸化窒素との組み合わせを含む組成物およびその使用 |
| JP2017503762A (ja) | 2013-03-15 | 2017-02-02 | マリンクロット ホスピタル プロダクツ アイピー リミテッド | ｅｘ ｖｉｖｏ液状物中への一酸化窒素の投与及びモニタリング |
| US20170215411A1 (en) | 2013-03-15 | 2017-08-03 | Mallinckrodt Hospital Products IP Limited | Administration and monitoring of nitric oxide in ex vivo fluids |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3672403A4 (en) | 2021-05-19 |
| KR20240142604A (ko) | 2024-09-30 |
| JP2020531529A (ja) | 2020-11-05 |
| AU2018322317A1 (en) | 2020-03-12 |
| KR102708577B1 (ko) | 2024-09-24 |
| AU2024200468A1 (en) | 2024-02-15 |
| US12285008B2 (en) | 2025-04-29 |
| CA3073399A1 (en) | 2019-02-28 |
| US20190059359A1 (en) | 2019-02-28 |
| US11950590B2 (en) | 2024-04-09 |
| US20240138399A1 (en) | 2024-05-02 |
| US20250228235A1 (en) | 2025-07-17 |
| US20210321605A1 (en) | 2021-10-21 |
| JP2022140622A (ja) | 2022-09-26 |
| MX2020001853A (es) | 2020-08-03 |
| US11044904B2 (en) | 2021-06-29 |
| EP3672403A1 (en) | 2020-07-01 |
| CN111107742A (zh) | 2020-05-05 |
| AU2018322317B2 (en) | 2023-11-23 |
| KR20200041359A (ko) | 2020-04-21 |
| WO2019040921A1 (en) | 2019-02-28 |
| JP2024159817A (ja) | 2024-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022140622A (ja) | 器官の生存率を改善する方法 | |
| AU2019246828B2 (en) | Administration and monitoring of nitric oxide in ex vivo fluids | |
| US12052987B2 (en) | Administration and monitoring of nitric oxide in ex vivo fluids | |
| Hijiya et al. | Bronchodilator inhalation during ex vivo lung perfusion improves posttransplant graft function after warm ischemia | |
| JP2025179164A (ja) | 器官の生存率を改善する方法 | |
| Downing et al. | Acute physiological changes following heart-lung allotransplantation in dogs | |
| Krueger et al. | Ex vivo lung perfusion | |
| Hijiya | BRONCHODILATOR INHALATION DURING EVLP IMPROVES POST-TRANSPLANT GRAFT FUNCTION FOLLOWING WARM ISCHEMIA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210624 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210624 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220428 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220506 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220802 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221104 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230202 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230301 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230317 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7249331 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |